Genzyme Teams With French Firm to Combat Blindness

Cambridge, MA-based biotech giant Genzyme (NASDAQ: GENZ) has forged a research agreement with French startup Fovea Pharmaceuticals. The deal—financial terms of which were not disclosed—is aimed a developing gene-based therapies for preventing or ameliorating blindness.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy